🇺🇸 HALO — Halozyme Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

128,62 USD

Máx. histórico

131,18

5 días

Caída desde máximo

-1,95%

Rango 52 semanas

61,23 – 134,00

Variación hoy

-0,26%

Cierre anterior

128,95

Rango de hoy

128,26 – 131,36

Volumen hoy

1.412.955

Peor caída histórica

-74,26%

05/06/2007 → 04/12/2008

Recuperado en 1154 días

Volatilidad anualizada ⓘ

57,99%

Información
Nombre completo
Halozyme Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
423
PER ⓘ
37,61 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
108,89 USD (puede no estar actualizado)
Primera cotización
16/03/2004
Precio actualizado
hace 18 horas
Sobre la empresa

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
17/01/2025 55,66 55,73 54,77 54,80 -1,03% 1,72% 942.000
16/01/2025 54,64 55,79 54,64 55,37 +1,58% 2,10% 1.570.000
15/01/2025 54,39 55,30 54,05 54,51 +1,26% 2,30% 1.959.500
14/01/2025 54,74 54,87 53,26 53,83 -0,57% 2,94% 1.360.900
13/01/2025 52,65 54,84 52,23 54,14 +2,54% 4,96% 2.016.100
10/01/2025 53,95 53,99 52,66 52,80 -1,79% 2,47% 2.146.600
08/01/2025 54,12 55,00 51,91 53,76 +5,02% 5,71% 2.669.900
07/01/2025 51,00 51,73 50,36 51,19 +1,35% 2,69% 1.790.200
06/01/2025 47,75 50,82 47,75 50,51 +5,80% 6,43% 1.893.900
03/01/2025 48,20 48,53 47,52 47,74 -0,56% 2,10% 993.000
02/01/2025 48,23 49,00 47,86 48,01 +0,42% 2,36% 1.210.300
31/12/2024 48,20 48,72 47,72 47,81 -0,38% 2,07% 842.700
30/12/2024 48,65 48,80 47,65 47,99 -0,29% 2,36% 891.500
27/12/2024 47,60 48,26 47,56 48,13 +0,21% 1,47% 946.100
26/12/2024 47,47 48,24 47,00 48,03 +1,03% 2,61% 762.300
24/12/2024 47,25 47,63 46,76 47,54 +0,81% 1,84% 308.700
23/12/2024 46,77 47,34 46,26 47,16 +0,43% 2,31% 1.451.600
20/12/2024 47,03 48,21 46,88 46,96 -0,76% 2,83% 4.794.700
19/12/2024 46,94 48,11 46,90 47,32 +1,02% 2,58% 1.754.800
18/12/2024 48,66 49,60 46,45 46,84 -3,62% 6,47% 1.850.100
17/12/2024 47,58 48,82 47,55 48,60 +1,19% 2,67% 1.333.400
16/12/2024 48,10 48,88 47,70 48,03 +0,06% 2,45% 2.213.300
13/12/2024 47,32 48,31 47,31 48,00 +0,36% 2,11% 932.100
12/12/2024 47,39 48,64 47,39 47,83 +0,93% 2,64% 927.700
11/12/2024 49,24 49,35 47,08 47,39 -3,40% 4,61% 1.242.500
10/12/2024 49,26 49,79 48,32 49,06 +0,00% 2,98% 1.103.900
09/12/2024 48,20 49,27 47,84 49,06 +1,36% 2,97% 867.200
06/12/2024 48,40 49,05 48,14 48,40 +0,71% 1,88% 905.800
05/12/2024 48,10 48,64 47,36 48,06 -1,13% 2,66% 1.025.600
04/12/2024 48,76 49,08 48,43 48,61 +0,27% 1,33% 786.300